Literature DB >> 34314823

Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life.

Aaron J Cohen1, Kanako Teramoto2, Brian Claggett3, Leo Buckley3, Scott Solomon3, Christie Ballantyne4, Elizabeth Selvin5, Amil M Shah6.   

Abstract

BACKGROUND: Epidemiologic data supporting the association of accumulated inflammation from mid- to late life with late-life risk of cardiac dysfunction and heart failure (HF) is limited. METHODS AND
RESULTS: Among 4011 participants in the Atherosclerosis Risk in Communities study who were free of prevalent cardiovascular disease at study Visit 5, accumulated inflammation was defined as time-averaged high-sensitivity c-reactive protein (hsCRP) over 3 visits spanning 1990 to 2013. Associations with left ventricular (LV) function at Visit 5 and with incident adjudicated HF post Visit 5 were assessed using linear and Cox regression, adjusting for demographics and comorbidities. Higher accumulated hsCRP was associated with greater LV mass index, lower e', higher E/e', and higher adjusting for demographics (all P ≤0.01), but only with higher pulmonary artery systolic pressure after adjustment for comorbidities (P = 0.024). At 5.3 ± 1.2 year follow-up, higher accumulated hsCRP was associated with greater risk of incident HF (HR 1.31 [95% CI 1.18-1.47], P < 0.001), HFrEF (1.26 [1.05-1.52], P = 0.01), and HFpEF (1.30 [1.11-1.53], P = 0.001) in demographic-adjusted models, but not after adjustment for comorbidities (all P > 0.10). Only Visit 5 hsCRP remained associated with incident HF (1.12 [1.02-1.24], P = 0.02) after full adjustment.
CONCLUSIONS: Greater accumulated inflammation is associated with worse LV function and heightened HF risk in late-life. These relationships are attenuated after adjusting for HF risk factors. Published by Elsevier Inc.

Entities:  

Keywords:  echocardiography; heart failure; hsCRP; inflammation

Mesh:

Year:  2021        PMID: 34314823      PMCID: PMC8823406          DOI: 10.1016/j.cardfail.2021.07.006

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  54 in total

1.  Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

Authors:  Sameer Ather; Wenyaw Chan; Biykem Bozkurt; David Aguilar; Kumudha Ramasubbu; Amit A Zachariah; Xander H T Wehrens; Anita Deswal
Journal:  J Am Coll Cardiol       Date:  2012-03-13       Impact factor: 24.094

2.  The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study.

Authors:  Keenan A Walker; B Gwen Windham; Charles H Brown; David S Knopman; Clifford R Jack; Thomas H Mosley; Elizabeth Selvin; Dean F Wong; Timothy M Hughes; Yun Zhou; Alden L Gross; Rebecca F Gottesman
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Absolute and attributable risks of heart failure incidence in relation to optimal risk factors.

Authors:  Aaron R Folsom; Kazumasa Yamagishi; Atsushi Hozawa; Lloyd E Chambless
Journal:  Circ Heart Fail       Date:  2009-01       Impact factor: 8.790

4.  Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin.

Authors:  Michael R Zile; Catalin F Baicu; John S Ikonomidis; Robert E Stroud; Paul J Nietert; Amy D Bradshaw; Rebecca Slater; Bradley M Palmer; Peter Van Buren; Markus Meyer; Margaret M Redfield; David A Bull; Henk L Granzier; Martin M LeWinter
Journal:  Circulation       Date:  2015-01-30       Impact factor: 29.690

5.  Low myocardial protein kinase G activity in heart failure with preserved ejection fraction.

Authors:  Loek van Heerebeek; Nazha Hamdani; Inês Falcão-Pires; Adelino F Leite-Moreira; Mark P V Begieneman; Jean G F Bronzwaer; Jolanda van der Velden; Ger J M Stienen; Gerrit J Laarman; Aernout Somsen; Freek W A Verheugt; Hans W M Niessen; Walter J Paulus
Journal:  Circulation       Date:  2012-07-17       Impact factor: 29.690

Review 6.  Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction.

Authors:  Anupam A Kumar; Daniel P Kelly; Julio A Chirinos
Journal:  Circulation       Date:  2019-03-12       Impact factor: 29.690

7.  Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.

Authors:  Amil M Shah; Brian Claggett; Laura R Loehr; Patricia P Chang; Kunihiro Matsushita; Dalane Kitzman; Suma Konety; Anna Kucharska-Newton; Carla A Sueta; Thomas H Mosley; Jacqueline D Wright; Joseph Coresh; Gerardo Heiss; Aaron R Folsom; Scott D Solomon
Journal:  Circulation       Date:  2016-11-23       Impact factor: 29.690

8.  High-sensitivity C-reactive protein and parameters of left ventricular dysfunction.

Authors:  Sanjiv J Shah; Gregory M Marcus; Ivor L Gerber; Barry H McKeown; Joshua C Vessey; Mark V Jordan; Michele Huddleston; Elyse Foster; Kanu Chatterjee; Andrew D Michaels
Journal:  J Card Fail       Date:  2006-02       Impact factor: 5.712

9.  Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy.

Authors:  Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

Review 10.  Obesity, inflammation, and heart failure: links and misconceptions.

Authors:  Filippos Triposkiadis; Andrew Xanthopoulos; Randall C Starling; Efstathios Iliodromitis
Journal:  Heart Fail Rev       Date:  2021-04-07       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.